The invention pertains to a method for treating a neoplasm, such as colorectal cancer, using hollow silica spheres (“HSS”). It also is directed to a method for making uncalcined HSS, calcined HSS from which phenyl groups have been removed, and HSS incorporating particles of Fe.sub.3O.sub.4, as well as compositions containing HSS

The invention pertains to a method for treating a neoplasm, such as colorectal cancer, using hollow silica spheres (“HSS”). It also is directed to a method for making uncalcined HSS, calcined HSS from which phenyl groups have been removed, and HSS incorporating particles of Fe.sub.3O.sub.4, as well as compositions containing HSS

The invention pertains to a method for treating a neoplasm, such as colorectal cancer, using hollow silica spheres (“HSS”). It also is directed to a method for making uncalcined HSS, calcined HSS from which phenyl groups have been removed, and HSS incorporating particles of Fe.sub.3O.sub.4, as well as compositions containing HSS.

The invention pertains to a method for treating a neoplasm, such as colorectal cancer, using hollow silica spheres (“HSS”). It also is directed to a method for making uncalcined HSS, calcined HSS from which phenyl groups have been removed, and HSS incorporating particles of Fe.sub.3O.sub.4, as well as compositions containing HSS.

The present invention provides a composition, preferably a dietary or pharmaceutical composition, comprising or consisting of vitamin(s) (a), and optionally minerals (b), and a pharmaceutically or dietetically suitable carrier such as nutrients DHA and/or EPA (c), encapsulated in a soft gelatine such as a bovine, porcine, vegetable and succinylated gelatine shell, wherein the vitamin(s) include Vitamin C and said Vitamin C is, at least in part, in the form of an ascorbate salt such as, but not limited to, Calcium ascorbate or any other divalent cation salt such as Magnesium ascorbate.

The present invention provides a composition, preferably a dietary or pharmaceutical composition, comprising or consisting of vitamin(s) (a), and optionally minerals (b), and a pharmaceutically or dietetically suitable carrier such as nutrients DHA and/or EPA (c), encapsulated in a soft gelatine such as a bovine, porcine, vegetable and succinylated gelatine shell, wherein the vitamin(s) include Vitamin C and said Vitamin C is, at least in part, in the form of an ascorbate salt such as, but not limited to, Calcium ascorbate or any other divalent cation salt such as Magnesium ascorbate.

A composition comprising, for example, 1 wt-% to 10 wt-% curcumin or turmeric; 50 wt-% to 60 wt-% ginger; 10 wt-% to 20 wt-% ashwagandha; and 25 wt % to 30 wt % Tulsi herb, relative to the total weight of curcumin, ginger, ashwagandha and Tulsi herb, and methods of making and using the compositions, are provided.

A composition comprising, for example, 1 wt-% to 10 wt-% curcumin or turmeric; 50 wt-% to 60 wt-% ginger; 10 wt-% to 20 wt-% ashwagandha; and 25 wt % to 30 wt % Tulsi herb, relative to the total weight of curcumin, ginger, ashwagandha and Tulsi herb, and methods of making and using the compositions, are provided.

This invention provides mass spectrometry (MS) compatible nanomaterials for the selective capture and enrichment of low abundance proteins as well as MS analysis of different proteoforms of proteins, particularly cardiac proteins and different proteoforms of cardiac troponin I (cTnI) arising from post-translational modifications and sequence variations. The surface of superparamagnetic nanoparticles is functionalized with probe molecules that specifically bind to the desired protein. In an embodiment, the nanoparticles are functionalized with probe molecules having high affinity and selectivity for cTnI within the human cardiac troponin complex. This allows for MS-analysis and characterization of cTnI proteoforms from human heart tissue lysates and human blood or serum samples, and provides an accurate assay for detection of cTnI with molecular details. Such assays are useful for accurate diagnosis of acute coronary syndrome and chronic diseases, including acute myocardial infarction and other cardiac injuries, as well as risk stratification and outcome assessment for patients.

A monocyte, monocyte derived cell or macrophage infected with an oncolytic herpes simplex virus is disclosed together with uses of such infected cells in the treatment of diseases such as cancer.